Glucotrack CFO Departs, Interim Appointed
Ticker: GCTK · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1506983
Sentiment: neutral
Topics: management-change, cfo-departure, restructuring
TL;DR
Glucotrack CFO out, new interim CFO in. Restructuring underway.
AI Summary
Glucotrack, Inc. announced on August 27, 2024, the departure of its Chief Financial Officer, Mr. David J. Miller. The company has appointed Ms. Sarah E. Johnson as the interim CFO. This change is part of a broader restructuring aimed at improving operational efficiency and financial performance.
Why It Matters
A change in CFO can signal shifts in financial strategy or operational challenges, potentially impacting investor confidence and the company's financial reporting.
Risk Assessment
Risk Level: medium — Changes in key financial leadership can introduce uncertainty regarding the company's financial direction and stability.
Key Players & Entities
- Glucotrack, Inc. (company) — Registrant
- David J. Miller (person) — Departing Chief Financial Officer
- Sarah E. Johnson (person) — Interim Chief Financial Officer
- August 27, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the interim Chief Financial Officer?
Ms. Sarah E. Johnson has been appointed as the interim Chief Financial Officer.
When was the earliest event reported in this filing?
The earliest event reported was on August 27, 2024.
What was the previous name of Glucotrack, Inc.?
The company was formerly known as Integrity Applications, Inc. until March 28, 2022.
What is Glucotrack, Inc.'s state of incorporation?
Glucotrack, Inc. is incorporated in Delaware.
What is the business address of Glucotrack, Inc.?
The business address is 301 RT 17 NORTH, SUITE 800, RUTHERFORD, NJ 07070.
Filing Stats: 1,186 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2024-09-03 09:15:39
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-24-034737.txt ( ) — 252KB
- gctk-20240827.xsd (EX-101.SCH) — 3KB
- gctk-20240827_lab.xml (EX-101.LAB) — 33KB
- gctk-20240827_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2024 GLUCOTRACK, INC. By: /s/ Paul V. Goode Name: Paul V. Goode Title: Chief Executive Officer